Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease

Toxicology

Volumn 319, Issue 1, 2014, Pages 38-43

  Pérez H, Jesús ^a,b   Carrillo S, Carlos ^a   García, Esperanza ^c   Ruiz Mar, Gabriela ^a   Pérez Tamayo, Ruy ^a   Chavarría, Anahí ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Neuroprotection; Parkinson's disease; Silymarin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; SILYMARIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; NEUROPROTECTION; PARKINSON'S DISEASE; SILYMARIN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; SILYMARIN; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84896108793     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.02.009     Document Type: Article

References (26)

1. Baluchnejadmojarad T., Roghani M., Mafakheri M. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci. Lett. 2010, 480:206-210.
2. De Girolamo L., Hargreaves A.J., Billett E.E. Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. J. Neurochem. 2001, 76:650-660.
3. Dexter D.T., Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 2013, 62:132-144.
4. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 2002, 81:1285-1297.
5. Garcia E., Rios C., Sotelo J. Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice. Neurochem. Res. 1992, 17:979-982.
6. Garcia E., Limon D., Perez-De La Cruz V., Giordano M., Diaz-Muñoz M., Maldonado P.D., Herrera-Mundo M.N., Pedraza-Chaverri J., Santamaria A. Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine. Free Radic. Biol. Res. 2008, 10:892-902.
7. Garcia E., Villeda-Hernández J., Pedraza-Chaverrí J., Maldonado P.D., Santamaría A. S-allylcysteine reduces the MPTP-induced striatal cell damage via inhibition of pro-inflammatory cytokine tumor necrosis factor-α and inducible nitric oxide synthase expressions in mice. Phytomedicine 2010, 18:65-73.
8. Gazák R., Walterová D., Kren V. Silybin and silymarin - new and emerging applications in medicine. Curr. Med. Chem. 2007, 14:315-338.
9. Green P.S., Gridley K.E., Simpkins J.W. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci. Lett. 1996, 218:165-168.
10. Johnson V., Osuchowski M., He Q., Sharma R. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. Alterations in thymic differentiation correlate with changes in c-myc gene expression. Planta Med. 2002, 68:961-965.
11. Loguercio C., Festi D. Silybin and the liver: from basic research to clinical practice. World J. Gastroenterol. 2011, 17:2288-2301.
12. Lu P., Mamiya T., Lu L.L., Mouri A., Zou L., Nagai T., Hiramatsu M., Ikejima T., Nabeshima T. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br. J. Pharmacol. 2009, 157:1270-1277.
13. Lu P., Mamiya T., Lu L., Mouri A., Niwa M., Kim H.C., Zou L.B., Nagai T., Yamada K., Ikejima T., Nabeshima T. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav. Brain Res. 2010, 207:387-393.
14. Malekinejad H., Rahmani F., Valivande-Azar S., Taheri-Broujerdi M., Bazargani-Gilani B. Long-term administration of Silymarin augments proinflammatory mediators in the hippocampus of rats: evidence for antioxidant and pro-oxidant effects. Hum. Exp. Toxicol. 2012, 31:921-930.
15. Nencini C., Giorgi G., Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007, 14:129-135.
16. Raza S.S., Khan M.M., Ashafaq M., Ahmad A., Khuwaja G., Khan A., Siddiqui M.S., Safhi M.M., Islam F. Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: a behavioral, biochemical and immunohistological study in Wistar rats. J. Neurol. Sci. 2011, 309:45-54.
17. Ramirez A.D., Liu X., Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003, 77:223-231.
18. Singhal N.K., Srivastava G., Patel D.K., Jain S.K., Singh M.P. Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. J. Pineal. Res. 2011, 50:97-109.
19. Singhal N.K., Chauhan A.K., Jain S.K., Shanker R., Singh C., Singh M.P. Silymarin- and melatonin-mediated changes in the expression of selected genes in pesticides-induced Parkinsonism. Mol. Cell. Biochem. 2013, 10.1007/s11010-013-1780-x.
20. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Mol. Brain Res. 2005, 134:57-66.
21. Vázquez-Claverie M., Garrido-Gil P., San Sebastián W., Izal-Azcárate A., Belzunegui S., Marcilla I., López B., Luquin M.R. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J. Neuropathol. Exp. Neurol. 2009, 68:977-984.
22. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., Jeng K.C. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. Neurosci. 2002, 16:2103-2112.
23. Wang X.H., Lu G., Hu X., Tsang K.S., Kwong W.H., Wu F.X., Meng H.W., Jiang S., Liu S.W., Ng H.K., Poon W.S. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease. BMC Neurosci. 2012, 14:142-155.
24. Welshons W.V., Thayer K.A., Judy B.M., Taylor J.A., Curran E.M., vom Saal F.S. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ. Health Perspect. 2003, 111:994-1006.
25. Wu J.W., Lin L.C., Hung S.C., Chi C.W., Tsai T.H. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J. Pharm. Biomed. Anal. 2007, 45:635-641.
26. Zhu H.J., Brinda B.J., Chavin K.D., Bernstein H.J., Patrick K.S., Markowitz J.S. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug. Metab. Dispos. 2013, 41:1679-1685.